OrganOx Secures £160 Million to Advance Transplant Technology
Revolutionizing Organ Transplantation: The Rise of OrganOx
In an era where medical innovation meets urgent healthcare needs, OrganOx stands out as a beacon of advancement. The Oxford, UK-based company has successfully raised an undisclosed amount of funding from notable investors such as Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC. This funding is a significant step for Startup founders and investors alike, as it underscores the growing interest in solutions for acute and chronic organ failure, a pressing global health crisis.
OrganOx, established from the esteemed University of Oxford in 2008, is pioneering technologies that dramatically enhance patient outcomes in organ transplantation.
The company’s executive chairman, Oern R. Stuge, MD, MBA, is leading the charge to expand operations and accelerate development efforts with the new capital. The company’s flagship product, the OrganOx metra, represents a breakthrough in organ preservation. This normothermic machine perfusion (NMP) platform is already approved in key markets including the U.S., Europe, Canada, and Australia, demonstrating OrganOx’s commitment to pushing the boundaries of medical technology.
With over 5,000 liver transplants successfully aided by the OrganOx metra, the platform is designed to keep donor livers in a metabolically active state outside the body. This innovation not only increases preservation times but also allows for functional assessment of the organs prior to transplant. The company is eyeing expansive growth opportunities in the flourishing market for organ technology, particularly after raising an impressive $160 million in primary and secondary equity financing as of February 24, 2025. For investors recognizing the potential of such cutting-edge technology, the future looks bright, revealing a landscape filled with unprecedented opportunities in the realm of human health and organ transplantation.
Key Terms Explained
- Investors
- Individuals or institutions that provide capital to start or expand a business in exchange for financial returns or ownership stake. In this case, Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC have invested in OrganOx.
- Equity Financing
- A method of raising funds for a company by selling shares or stock to investors, thereby giving them partial ownership. OrganOx has raised $160 million in primary and secondary equity financing.
- Normothermic Machine Perfusion (NMP)
- A technique used in organ transplantation for the preservation and assessment of organs. It keeps the organs in a metabolically active state outside the body, as demonstrated by OrganOx’s flagship product, the OrganOx metra.
Frequently Asked Questions
- Who are some of the notable investors in OrganOx?-Some of the notable investors in OrganOx include Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC.
- What is the significance of the funding OrganOx has received?+
- What is OrganOx's flagship product and what does it do?+
- What markets is the OrganOx metra approved in?+
- How much did OrganOx raise in primary and secondary equity financing?+
They've invested in OrganOx
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK